Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.
The investigators have already inquired if inhibiting rTMS QP over the visual cortex determines a reduction of frequency of migraine in a previous study. After 2 weekly sessions for a month, the investigators demonstrated a reduction of 47% in migraine frequency. In this study, the investigators aim to compare rTMS QP effect with the placebo effect and to evaluate if rTMS QP is capable to induce changes in VEP, CHEPS and QST.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Super Rapid Magstim Stimulator rTMS QP | Active Comparator | rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients |
|
| Placebo | Placebo Comparator | rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Super Rapid Magstim Stimulator | Device | The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity. The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of migraine | The investigators evaluate the frequency of migraine during the treatment and 2 months after its end. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Intensity of migraine | The investigators evaluate the intensity of migraine during the treatment and 2 months after its end | 12 months |
| Acute medication intake | The investigators evaluate acute medication intake during the treatment and 2 months after its end |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean Schoenen, HP | University of Liege | Principal Investigator |
| Delphine Magis, MD,PhD | University of Liege | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Roberta Baschi | Liège | 4000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Super Rapid Magstim Stimulator (sham) | Device | coil perpendicular to the scalp |
|
| 12 months |
| Attack duration | The investigators evaluate attack duration during the treatment and 2 months after its end | 12 months |
| Scores on psychological scales | The investigators evaluate scores on psychological scales during the treatment and 2 months after its end | 12 months |